KRAS and BRAF mutational analyses in a phase II trial of first-line FOLFOXIRI plus bevacizumab (BV) in metastatic colorectal cancer (mCRC) patients (pts)

被引：2
|
作者：
Salvatore, L. [1 ]
Loupakis, F. [1 ]
Fontanini, G. [2 ]
Cremolini, C. [1 ]
Stasi, I. [3 ]
Fabbri, A. [4 ]
Ciarlo, A. [5 ]
Granetto, C. [6 ]
Basolo, F. [2 ]
Falcone, A. [7 ]
机构：
[1] Univ Pisana, Azienda Osped, UO Oncol Med Univ 2, Ist Toscano Tumori, Pisa, Italy
[2] Univ Pisana, Azienda Osped, UO Anat Patol Sperimentale Univ, Pisa, Italy
[3] Azienda USL 6, UO Oncol Med, Ist Toscano Tumori, Livorno, Italy
[4] Univ Roma La Sapienza, Dipartimento Med Sperimentale & Patol Oncol Med, Rome, Italy
[5] Osped Misericordia & Dolce, UO Oncol Med, Prato, Italy
[6] Osped S Croce & Carle, UO ONcol Med, Cuneo, Italy
[7] Univ Pisa, Dipartimento Oncol Trapianti & Nuove Tecnol Med, Pisa, Italy
来源：
EJC SUPPLEMENTS | 2009年 / 7卷 / 02期
关键词：
D O I：
10.1016/S1359-6349(09)71155-3
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：339 / 339
页数：1
相关论文
共 50 条
  • [21] A phase II trial of a biweekly schedule of capecitabine (X) plus irinotecan (1) as first-line treatment in patients (pts) with metastatic colorectal cancer (MCRC).
    Garcia-Alfonso, P
    Perez-Manga, G
    Gonzalez, MC
    Lopez, P
    Gonzalez, E
    Belon, J
    Molina, M
    Pachon, V
    Iglesias, L
    Siso, I
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 256S - 256S
  • [22] A multicenter randomized phase II trial comparing CAPOXIRI plus bevacizumab with FOLFOXIRI plus bevacizumab as first-line treatment in patients with metastatic colorectal cancer: Primary results of the QUATTRO-II study
    Bando, Hideaki
    Satake, Hironaga
    Kotani, Daisuke
    Hamaguchi, Tetsuya
    Shiozawa, Manabu
    Ikumoto, Taro
    Okita, Yoshihiro
    Masuishi, Toshiki
    Kagawa, Yoshinori
    Yasui, Hisateru
    Oki, Eiji
    Komatsu, Yoshito
    Taniguchi, Hiroya
    Muro, Kei
    Kotaka, Masahito
    Yamazaki, Kentaro
    Misumi, Toshihiro
    Yoshino, Takayuki
    Kato, Takeshi
    Tsuji, Akihito
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [23] Quattro-II study: A multicenter randomized phase II study comparing capoxiri plus bevacizumab with FOLFOXIRI plus bevacizumab in patients with metastatic colorectal cancer as the first-line treatment
    Tsuji, Akihito
    Yoshino, Takayuki
    Yamanaka, Takeharu
    Bando, Hideaki
    Satake, Hironaga
    Yamazaki, Kentaro
    Taniguchi, Hiroya
    Oki, Eiji
    Kotaka, Masahito
    Oba, Koji
    Miyata, Yoshinori
    Muro, Kei
    Komatsu, Yoshito
    Baba, Hideo
    Kato, Takeshi
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [24] Capecitabine plus irinotecan (CAPIRI) as first-line treatment for patients (Pts) with metastatic colorectal cancer (MCRC)
    Laudani, A.
    Savio, G.
    Leonardi, V.
    Palmisano, V.
    Tartaglia, L.
    Manuguerra, G.
    Pepe, A.
    Alu, M.
    Usset, A.
    Agostara, B.
    [J]. ANNALS OF ONCOLOGY, 2007, 18 : 6 - 6
  • [25] Optimal Use of FOLFOXIRI Plus Bevacizumab as First-Line Systemic Treatment in Metastatic Colorectal Cancer
    Khatib, Jude
    Kainthla, Radhika
    [J]. CURRENT COLORECTAL CANCER REPORTS, 2020, 16 (04) : 89 - 95
  • [26] FOLFOXIRI/bevacizumab (bev) versus FOLFIRI/bev as first-line treatment in unresectable metastatic colorectal cancer (mCRC) patients (pts): Results of the phase III TRIBE trial by GONO group.
    Falcone, Alfredo
    Cremolini, Chiara
    Masi, Gianluca
    Lonardi, Sara
    Zagonel, Vittorina
    Salvatore, Lisa
    Trenta, Patrizia
    Tomasello, Gianluca
    Ronzoni, Monica
    Ciuffreda, Libero
    Zaniboni, Alberto
    Tonini, Giuseppe
    Buonadonna, Angela
    Valsuani, Chiara
    Chiara, Silvana
    Carlomagno, Chiara
    Boni, Corrado
    Marcucci, Lorenzo
    Boni, Luca
    Loupakis, Fotios
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [27] A phase III comparison of FOLFOXIRI to FOLFIRI as first-line treatment of metastatic colorectal cancer (MCRC)
    Masi, G.
    Brunetti, I
    Murr, R.
    Benedetti, G.
    Evangelista, W.
    Picone, V
    Chiara, S.
    Merlano, M.
    Vitello, S.
    Falcone, A.
    [J]. ANNALS OF ONCOLOGY, 2006, 17 : 22 - 23
  • [28] Capecitabine plus irinotecan plus bevacizurnab as first-line therapy for patients (pts) with metastatic colorectal cancer (MCRC): preliminary phase II study results
    Beslija, S.
    Banjin, M.
    Jungic, S.
    Obralic, N.
    Kecman-Malcic, G.
    Rakita, I.
    Salkic, B.
    Pasic, A.
    Tinjic, L.
    Ajanovic, E.
    [J]. EJC SUPPLEMENTS, 2007, 5 (04): : 256 - 257
  • [29] Capecitabine plus irinotecan (CAPIRI) as first-line treatment for patients (PTS) with metastatic colorectal cancer (MCRC)
    Laudani, Agata
    Savio, Giuseppina
    Leonardi, Vita
    Palmisano, Valentina
    Rondello, Giacomo
    Alu, Massimiliano
    Pepe, Alessio
    Calabria, Caterina
    Usset, Antonella
    Agostara, Biagio
    [J]. ANNALS OF ONCOLOGY, 2006, 17 : 119 - 119
  • [30] FOLFOXIRI (Irinotecan, Oxaliplatin, and Infusional 5FU/LV) in Combination With Panitumumab (P) in the First-line Treatment of Metastatic Colorectal Cancer (mCRC) Patients (pts) Selected for KRAS, BRAF, NRas and HRas Mutational Status - a Phase II Study by the GONO Group
    Fornaro, L.
    Loupakis, F.
    Lonardi, S.
    Masi, G.
    Salvatore, L.
    Cremolini, C.
    Bergamo, F.
    Cappetta, A.
    Zagonel, V.
    Falcone, A.
    [J]. EUROPEAN JOURNAL OF CANCER, 2011, 47 : S420 - S420
12345